{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:27:02Z","timestamp":1791664022491,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"suppl_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,1]]},"DOI":"10.1093\/cid\/cis499","type":"journal-article","created":{"date-parts":[[2012,7,2]],"date-time":"2012-07-02T16:19:01Z","timestamp":1341245941000},"page":"S93-S103","source":"Crossref","is-referenced-by-count":227,"title":["Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials"],"prefix":"10.1093","volume":"55","author":[{"given":"Derrick W.","family":"Crook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sarah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Kean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Stoesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette C.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherwood L.","family":"Gorbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E. A.","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,8,1]]},"reference":[{"key":"key\n\t\t\t\t20171013233422_CIS499C1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013233422_CIS499C2","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa051639","article-title":"A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality","volume":"353","author":"Loo","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013233422_CIS499C3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/502539","article-title":"A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use","volume":"26","author":"Muto","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171013233422_CIS499C4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":"Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole","volume":"40","author":"Musher","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C5","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","author":"Pepin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C7","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/522654","article-title":"Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive \u201cbundle\u201d approach","volume":"45","author":"Muto","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","article-title":"Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis","volume":"2","author":"Teasley","year":"1983","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171013233422_CIS499C9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/22.5.813","article-title":"Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea","volume":"22","author":"Wenisch","year":"1996","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes","volume":"58","author":"Johnson","year":"2009","journal-title":"J Infect"},{"key":"key\n\t\t\t\t20171013233422_CIS499C11","first-page":"168","article-title":"Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic","volume":"8","author":"Johnson","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"key\n\t\t\t\t20171013233422_CIS499C12","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":"In vitro activity of OPT-80 against Clostridium difficile","volume":"48","author":"Ackermann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233422_CIS499C13","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","article-title":"Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species","volume":"48","author":"Credito","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233422_CIS499C14","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233422_CIS499C15","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233422_CIS499C16","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/AAC.00476-08","article-title":"In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile","volume":"52","author":"Karlowsky","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233422_CIS499C17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171013233422_CIS499C18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/QAD.0b013e3282f5556d","article-title":"Designing and interpreting HIV noninferiority trials in naive and experienced patients","volume":"22","author":"Hill","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171013233422_CIS499C20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00002030-200402200-00001","article-title":"Drug switching and virologic-based endpoints in trials of antiretroviral drugs for HIV infection","volume":"18","author":"Phillips","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20171013233422_CIS499C21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1740774509356117","article-title":"Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field","volume":"7","author":"Wittkop","year":"2010","journal-title":"Clin Trials"},{"key":"key\n\t\t\t\t20171013233422_CIS499C22","volume-title":"Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile","author":"Babakhani","year":"2004"},{"key":"key\n\t\t\t\t20171013233422_CIS499C23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171013233422_CIS499C24","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","article-title":"A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin","volume":"156","author":"Tannock","year":"2010","journal-title":"Microbiology"},{"key":"key\n\t\t\t\t20171013233422_CIS499C25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.3174\/ajnr.A2442","article-title":"The problem of subgroup analyses: an example from a trial on ruptured intracranial aneurysms","volume":"32","author":"Naggara","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"key\n\t\t\t\t20171013233422_CIS499C26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1086\/649213","article-title":"Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality","volume":"50","author":"Miller","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1086\/511792","article-title":"Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system","volume":"28","author":"Dubberke","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171013233422_CIS499C28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3201\/eid1503.080312","article-title":"Clinical risk factors for severe Clostridium difficile-associated disease","volume":"15","author":"Henrich","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171013233422_CIS499C29","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/55\/suppl_2\/S93\/20911212\/cis499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T23:34:28Z","timestamp":1507937668000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/55\/suppl_2\/S93\/436657\/Fidaxomicin-Versus-Vancomycin-for-Clostridium"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,1]]},"references-count":29,"journal-issue":{"issue":"suppl_2","published-online":{"date-parts":[[2012,8,1]]},"published-print":{"date-parts":[[2012,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cis499","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717958341.793463038","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717958341.793463930","asserted-by":"object"}]},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2012,8,1]]},"published":{"date-parts":[[2012,8,1]]}}}